A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Golcadomide
DRUG: Rituximab
DRUG: Lenalidomide
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone/Prednisolone
DRUG: Bendamustine

Sponsor

Celgene